ANAHEIM, CA, May 01, 2019 (GLOBE NEWSWIRE) -- ^via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has unveiled its new UnCraveRx™ Weight Loss Program and appointed Dr. Kenneth Orbeck as Medical Director. UnCraveRx™ is a novel weight loss program that combines medically assisted weight loss management with lifestyle behavioral support.  

The UnCraveRx™ specialized weight loss program is expected to launch on October 1, 2019.The goal of the program is to help participants achieve healthy, sustainable weight goals. UnCraveRx™ will combine a naltrexone pellet insertion procedure performed by a licensed medical professional. Naltrexone can reduce food cravings as reported by individuals who took part in several pilot weight loss programs. The second part of the program is a lifestyle behavioral therapy and nutritional coaching. Program participants will immediately begin working with a coach to develop a roadmap for success. 

Dr. Kenneth Orbeck owns and operates an integrative and functional medical center in South Carolina. His practice is based in bio identical hormone therapy; BodyLogicMD of Greenville and Greenville Rejuvenation, Dr. Orbeck dedicates his practice to helping women and men find relief from hormonal imbalances such as menopause, andropause (the male menopause), adrenal fatigue and thyroid disorders by using a personal functional approach to wellness, combining customized nutrition and fitness regimens with bio identical hormone therapy. Dr. Orbeck believes that proper diet, regular exercise and balanced hormones are the cornerstones of longevity. Dr. Orbeck examines the interaction between a person's genetic, environmental, and lifestyle factors for an individualized treatment plan on each patient. Dr. Orbeck utilizes advanced hormonal application through subcutaneous pellet therapy and is a national speaker on advanced hormone and pellet therapy. Dr. Kenneth Orbeck received his undergraduate degree from Calvin College in 1983 and completed his Doctorate in Osteopathic Medicine at the University of Osteopathic Medicine and Health Sciences in 1987, where he served as student chairman for the American College of General Practitioners. Before practicing medicine, Dr. Orbeck fulfilled his post graduate training at Mt. Clemens General Hospital in 1988. Dr. Orbeck is a fellow in Anti-aging, Regenerative Medicine (FAAFM), and is certified by the American board of Anti-aging and Regenerative Medicine (ABAARM).

Dr. Kenneth Orbeck stated, “As a physician working in integrative and functional medicine, I encounter individuals who are seeking optimal health. One of the greatest challenges and concerns of many patients is regarding their weight. Weight abnormalities are complex and require a comprehensive approach to achieve recovery and optimal metabolic health. Although many factors are involved in weight management, caloric intake must be addressed regarding a person's addiction to food or “need to feed.” Psychological issues play a very important role in oversized individuals as well. In the forefront of addiction medicine is the use of naltrexone, a proven treatment regimen that can curtail the severe cravings often encountered by victims of addiction. Although naltrexone has been proven highly effective, current application methods lack the desired consistent serum levels needed to avoid unnecessary side effects. Cutting edge developments have allowed the use of naltrexone to be inserted through subcutaneous application which ensures constant drug delivery and controlled serum levels avoiding the unnecessary side effects. This exciting development has shown great promise in addiction medicine including weight management. I am very enthusiastic about the potential benefits that can now be offered to individuals suffering from weight and addiction issues.” 

Lourdes Felix, CFO, COO and Director, stated, “We are proud to announce launch of our new weight loss program and the addition of Dr. Kenneth Orbeck as Medical Director. We believe Dr. Orbeck will be invaluable to the program and will be instrumental in fulfilling UnCraveRx’s objective to help individuals who have struggled to maintain their weight loss over time, and to help those who would benefit from losing weight and building on their progress. Research has shown, individuals that struggle with excess weight are dealing with multifaceted circumstances of biological, genetic and behavioral factors. Our approach is unique and will be able to address the complexities of losing weight and helping individuals optimize their health and wellness.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders including two lead proprietary programs; The BioCorRx® Recovery Program (www.beataddiction.com) and UnCraveRx™ Weight Loss Program (www.UnCraveRx.com). The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com.

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com

Released May 1, 2019